On Oct. 19, 2020, Evotec announced that its Seattle-based subsidiary, Just – Evotec Biologics had received a grant from the Bill & Melinda Gates Foundation (Seattle, WA) as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries.